Establishment of order-made treatment using liver tumor PDX rad model which were implanted patient-derived HCC

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K07735
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52040:Radiological sciences-related
• Research Institution: Osaka Metropolitan University (2022-2023); Osaka City University (2021)
• Principal Investigator: Kageyama Ken 大阪公立大学, 大学院医学研究科, 講師 (70791862)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: PDX / 肝細胞癌

Outline of Final Research Achievements

Patient-derived tumor xenograft (PDX) model is a cancer therapy screening platform in which tumors removed from patients are transplanted directly into immunocompromised animals. PDX model will be established on rats capable of transcatheter intra-arterial administration to evaluate the efficacy of transarterial therapy in cancer treatment. (1) To create a PDX model of hepatocellular carcinoma (HCC) in which patient-derived hepatocellular carcinoma (HCC) tissue removed by surgery is directly transplanted orthotopically into the liver of immunocompromised rats. (2) To use this HCC-PDX model to replace individual patients in the treatment of HCC with IVR (interventional radiology) such as hepatic arterial injection and hepatic arterial embolization. (2) The HCC-PDX model will be used to explore effective treatments by administering IVR and molecular targeted drugs on behalf of individual patients.

Translated with DeepL.com (free version)

Free Research Field

PDXモデル

Academic Significance and Societal Importance of the Research Achievements

この研究により、患者それぞれの肝細胞癌治療に、最良の治療法を還元でき、患者個人に特化したオーダーメイド治療の実践を可能とする。